Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multi-center, Open-label, Single Arm Phase 2 Study to Evaluate the Efficacy, Safety, and Pharmacokinetic Characteristics of FCN-159 in Pediatric Patients With Refractory/Recurrent Langerhans Cell Histiocytosis

NCT05997602 is registered in ClinicalTrials.gov with Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd. as lead sponsor.

NCT NCT05997602
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05997602 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multi-center, Open-label, Single Arm Phase 2 Study to Evaluate the Efficacy, Safety, and Pharmacokinetic Characteristics of FCN-159 in Pediatric Patients With Refractory/Recurrent Langerhans Cell Histiocytosis
Lead sponsor
Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.
Phase
Phase 2
Overall status
Recruiting
Start date
September 28, 2023
Completion date
May 14, 2027
Enrollment
56 (estimated)
Sites
11

Conditions

As the registry lists them; a condition with its own page is linked.

langerhans cell histiocytosis, lch